ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019

Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET.

  • TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer:
    • positive safety review by independent data monitoring committee
    • opened for patient enrollment in the United States
    • first U.S. clinical sites activated
  • Princeton manufacturing facility ready for production of clinical batches
  • Cash position of €81.9 million ($89.2 million) at the end of September
Menu